Dyne Medical Group Joins Hands with Taiwan’s Lite-Med to Accelerate Asian Market Expansion of Disposable Flexible Ureteroscope ‘URUS’
FDA approval and international design awards validate competitiveness; global expansion and integrated stone-treatment solutions anticipated
Dyne Medical Group, a specialized Korean medical device company, has taken a significant step toward expanding its presence in the Asian market by partnering with a leading Taiwanese medical device company.
Disposable flexible ureteroscope ‘URUS’ (Photo courtesy of Dyne Medical Group)
Dyne Medical Group (CEO: Sung-hoon Lee) announced on the 26th that it has signed an official distribution agreement in Taiwan with Lite-Med Inc., a Taiwanese medical device company, for its disposable flexible ureteroscope, URUS. This agreement is being recognized as a key strategic partnership secured by Dyne Medical Group to accelerate the expansion of URUS across the Asian market.
Currently, Dyne Medical Group has established distributor agreements in Indonesia, Uzbekistan, Singapore, the United States, and Japan, steadily expanding its global network. Through the addition of Taiwan, the company expects to further strengthen its distribution and business foundation within Asia.
Founded in 1991, Lite-Med has over 30 years of experience supplying medical devices for stone treatment, including extracorporeal shock wave lithotripters (ESWL), to markets worldwide. The company is widely regarded as one of Taiwan’s representative medical device firms, with strong brand credibility in the field of urolithiasis treatment, an extensive local urology hospital and clinic network, and well-established capabilities in sales, distribution, and clinical collaboration.
The core product for Dyne Medical Group’s entry into the Taiwanese market, URUS, is a disposable flexible ureteroscope used for renal and ureteral stone treatment (RIRS).
Delivered in a pre-sterilized state and ready for immediate use upon opening, URUS fundamentally eliminates the risk of cross-contamination—one of the major drawbacks of reusable endoscopes. In addition, it reduces the time and costs associated with reprocessing, sterilization, and storage, driving rapid adoption by medical institutions worldwide.
Notably, URUS has received U.S. FDA 510(k) clearance, confirming its safety and performance on a global scale. It has also won the prestigious Red Dot Design Award, demonstrating excellence in user-centered design and operability.
Its proprietary 6 o’clock working channel structure further differentiates the product by enhancing both visual stability and instrument maneuverability, earning positive feedback from urologists around the world.
Regarding the agreement, a Dyne Medical Group representative stated,
“Lite-Med is one of the companies with the strongest sales capabilities and clinical networks in the field of stone treatment in Taiwan. This partnership goes beyond simple product supply and represents a core strategic alliance to foster the long-term growth of URUS in the Asian market.”
The representative added,
“Taiwan has the potential to serve as a key hub in Asia in terms of medical standards, reimbursement systems, and the speed of medical device adoption. Building on a successful launch in Taiwan, we plan to expand step by step into Japan and Southeast Asia.”
Lite-Med also expressed strong expectations for the collaboration. A company representative commented,
“By adding URUS to our extracorporeal shock wave lithotripsy portfolio, we will be able to establish a comprehensive stone-treatment solution lineup that covers everything from non-invasive therapy to endoscopic stone removal. We anticipate a very positive response from the Taiwanese medical community.”
Meanwhile, Dyne Medical Group emphasized that it views this expansion into Taiwan not merely as an export contract, but as a representative case of a Korean medical device company strengthening its global competitiveness under its own brand.
Going forward, the company plans to continue achieving stable overseas revenue growth by implementing localized sales, clinical, and distribution strategies based on region-specific professional partnerships.
Dyne Medical Group Joins Hands with Taiwan’s Lite-Med to Accelerate Asian Market Expansion of Disposable Flexible Ureteroscope ‘URUS’
FDA approval and international design awards validate competitiveness; global expansion and integrated stone-treatment solutions anticipated
Dyne Medical Group, a specialized Korean medical device company, has taken a significant step toward expanding its presence in the Asian market by partnering with a leading Taiwanese medical device company.
Dyne Medical Group (CEO: Sung-hoon Lee) announced on the 26th that it has signed an official distribution agreement in Taiwan with Lite-Med Inc., a Taiwanese medical device company, for its disposable flexible ureteroscope, URUS. This agreement is being recognized as a key strategic partnership secured by Dyne Medical Group to accelerate the expansion of URUS across the Asian market.
Currently, Dyne Medical Group has established distributor agreements in Indonesia, Uzbekistan, Singapore, the United States, and Japan, steadily expanding its global network. Through the addition of Taiwan, the company expects to further strengthen its distribution and business foundation within Asia.
Founded in 1991, Lite-Med has over 30 years of experience supplying medical devices for stone treatment, including extracorporeal shock wave lithotripters (ESWL), to markets worldwide. The company is widely regarded as one of Taiwan’s representative medical device firms, with strong brand credibility in the field of urolithiasis treatment, an extensive local urology hospital and clinic network, and well-established capabilities in sales, distribution, and clinical collaboration.
The core product for Dyne Medical Group’s entry into the Taiwanese market, URUS, is a disposable flexible ureteroscope used for renal and ureteral stone treatment (RIRS).
Delivered in a pre-sterilized state and ready for immediate use upon opening, URUS fundamentally eliminates the risk of cross-contamination—one of the major drawbacks of reusable endoscopes. In addition, it reduces the time and costs associated with reprocessing, sterilization, and storage, driving rapid adoption by medical institutions worldwide.
Notably, URUS has received U.S. FDA 510(k) clearance, confirming its safety and performance on a global scale. It has also won the prestigious Red Dot Design Award, demonstrating excellence in user-centered design and operability.
Its proprietary 6 o’clock working channel structure further differentiates the product by enhancing both visual stability and instrument maneuverability, earning positive feedback from urologists around the world.
Regarding the agreement, a Dyne Medical Group representative stated,
“Lite-Med is one of the companies with the strongest sales capabilities and clinical networks in the field of stone treatment in Taiwan. This partnership goes beyond simple product supply and represents a core strategic alliance to foster the long-term growth of URUS in the Asian market.”
The representative added,
“Taiwan has the potential to serve as a key hub in Asia in terms of medical standards, reimbursement systems, and the speed of medical device adoption. Building on a successful launch in Taiwan, we plan to expand step by step into Japan and Southeast Asia.”
Lite-Med also expressed strong expectations for the collaboration. A company representative commented,
“By adding URUS to our extracorporeal shock wave lithotripsy portfolio, we will be able to establish a comprehensive stone-treatment solution lineup that covers everything from non-invasive therapy to endoscopic stone removal. We anticipate a very positive response from the Taiwanese medical community.”
Meanwhile, Dyne Medical Group emphasized that it views this expansion into Taiwan not merely as an export contract, but as a representative case of a Korean medical device company strengthening its global competitiveness under its own brand.
Going forward, the company plans to continue achieving stable overseas revenue growth by implementing localized sales, clinical, and distribution strategies based on region-specific professional partnerships.